CN116421725A - 一种多重疗法的抑菌复合材料及其制备方法与应用 - Google Patents
一种多重疗法的抑菌复合材料及其制备方法与应用 Download PDFInfo
- Publication number
- CN116421725A CN116421725A CN202310385310.9A CN202310385310A CN116421725A CN 116421725 A CN116421725 A CN 116421725A CN 202310385310 A CN202310385310 A CN 202310385310A CN 116421725 A CN116421725 A CN 116421725A
- Authority
- CN
- China
- Prior art keywords
- mos
- mno
- aiph
- therapy
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 49
- 239000002131 composite material Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 230000003385 bacteriostatic effect Effects 0.000 title claims abstract description 22
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical group O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims abstract description 111
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 35
- 239000002077 nanosphere Substances 0.000 claims abstract description 32
- 239000002114 nanocomposite Substances 0.000 claims abstract description 18
- 239000000017 hydrogel Substances 0.000 claims abstract description 16
- 230000029663 wound healing Effects 0.000 claims abstract description 13
- CWQXQMHSOZUFJS-UHFFFAOYSA-N molybdenum disulfide Chemical compound S=[Mo]=S CWQXQMHSOZUFJS-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052982 molybdenum disulfide Inorganic materials 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 230000001737 promoting effect Effects 0.000 claims abstract description 6
- 239000011258 core-shell material Substances 0.000 claims abstract description 5
- QYZFTMMPKCOTAN-UHFFFAOYSA-N n-[2-(2-hydroxyethylamino)ethyl]-2-[[1-[2-(2-hydroxyethylamino)ethylamino]-2-methyl-1-oxopropan-2-yl]diazenyl]-2-methylpropanamide Chemical group OCCNCCNC(=O)C(C)(C)N=NC(C)(C)C(=O)NCCNCCO QYZFTMMPKCOTAN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000008367 deionised water Substances 0.000 claims description 14
- 229910021641 deionized water Inorganic materials 0.000 claims description 14
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 125000004386 diacrylate group Chemical group 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 239000004201 L-cysteine Substances 0.000 claims description 6
- 235000013878 L-cysteine Nutrition 0.000 claims description 6
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 claims description 5
- BTYIFQSAIPDZQW-UHFFFAOYSA-N 2-propan-2-yl-4,5-dihydro-1h-imidazole Chemical compound CC(C)C1=NCCN1 BTYIFQSAIPDZQW-UHFFFAOYSA-N 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 238000012719 thermal polymerization Methods 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000007626 photothermal therapy Methods 0.000 abstract description 16
- 206010052428 Wound Diseases 0.000 abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 abstract description 9
- 208000035143 Bacterial infection Diseases 0.000 abstract description 5
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000012567 medical material Substances 0.000 abstract description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical class CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- AMWRITDGCCNYAT-UHFFFAOYSA-L hydroxy(oxo)manganese;manganese Chemical compound [Mn].O[Mn]=O.O[Mn]=O AMWRITDGCCNYAT-UHFFFAOYSA-L 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000012221 photothermal agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000008542 thermal sensitivity Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本申请公开了一种多重疗法的抑菌复合材料及其制备方法与应用,属于医药材料领域。该多重疗法的抑菌复合材料为核壳结构,其内核为具有高光热转换效率的二硫化钼纳米球,中间层为通过静电作用吸附的二氧化锰,外层为2,2’‑偶氮双[2‑(2‑咪唑啉‑2‑基)丙烷]二盐酸盐,最终形成MoS2/MnO2‑AIPH纳米复合材料。将该复合材料用于抑菌,能够同时进行光热疗法和化学动力学疗法,还可以协同发挥作用,进一步提高抑菌效率。进一步将其制备成水凝胶,能够保持伤口周围湿润的环境,促进伤口愈合。此外,还具有优异的生物安全性和生物相容性,能够有效地促进伤口愈合,对于在临床环境中治疗细菌感染和促进伤口愈合具有重要意义。
Description
技术领域
本申请属于医药材料技术领域,具体涉及一种多重疗法的抑菌复合材料及其制备方法与应用。
背景技术
细菌感染,特别是多药耐药(multidrug resistance,MDR)细菌感染,每年夺走数百万人的生命,对全球公共卫生构成了严重威胁。临床上,通常使用抗生素进行细菌感染得治疗,但滥用抗生素使得细菌对某些抗生素产生耐药机制。此外,由于多药耐药细菌的细胞外基质可以促进生物膜的生长,进一步形成保护性屏障,使得抗生素难以渗透,最终导致细菌耐药性增加约1000倍。
近年来,纳米抗菌材料作为小分子抗生素的替代品引起了人们的兴趣。许多基于纳米材料的新型抗菌工具也应运而生。其中,光热疗法(photothermal therapy,PTT)和化学动力学疗法(Chemodynamic therapy,CDT)已被广泛用作常规抗生素疗法的替代疗法。PTT是利用光热剂,如MoS2纳米球,产生的热能来达到杀菌的目的。但PTT会导致局部温度显著升高,从而对周围组织造成损害。虽然已经开发出能够防止高温引起的损伤的PTT药剂,但它们降低的光热容量并没有产生有效的细菌抑制。此外,单个PTT药剂往往不足以有效杀灭细菌。针对于此,组合、多模式抗菌系统已成为单剂PTT的必要替代方案。
与产生热量杀菌的PTT不同,CDT利用过渡金属催化过氧化氢(H2O2)产生有毒的羟基自由基(·OH),利用芬顿(Fenton)或类芬顿反应来抑制细菌。然而,生物膜中存在的高浓度谷胱甘肽(GSH)会清除这些自由基,这严重限制了CDT的抑菌效果。
发明内容
1.发明目的
本申请的目的在于提供一种多重疗法的抑菌复合材料及其制备方法与应用,该多重疗法的抑菌复合材料为核壳结构,其内核为具有较高光热转换效率的二硫化钼(MoS2)纳米球,中间层为通过静电吸附作用吸附在二硫化钼纳米球表面的二氧化锰(MnO2),外层为吸附在二氧化锰表面的2,2’-偶氮双[2-(2-咪唑啉-2-基)丙烷]二盐酸盐(AIPH),最终形成MoS2/MnO2-AIPH纳米复合材料(MMA)。将该复合材料用于抑菌,能够同时进行光热疗法和化学动力学疗法,还可以协同发挥作用,进一步提高抑菌效率。同时规避了传统抗生素引起的细菌耐药性问题。
2.技术方案
为了达到上述目的,本申请所采用的技术方案如下:
本申请提供了一种多重疗法的抑菌复合材料,该多重疗法的抑菌复合材料为核壳结构,其内核为具有较高光热转换效率的二硫化钼(MoS2)纳米球,中间层为通过静电吸附作用吸附在二硫化钼纳米球表面的二氧化锰(MnO2),外层为吸附在二氧化锰表面的2,2’-偶氮双[2-(2-咪唑啉-2-基)丙烷]二盐酸盐(AIPH),最终形成MoS2/MnO2-AIPH纳米复合材料(MMA),该复合材料在用于抑菌时,能够同时进行光热疗法和化学动力学疗法,还可以协同发挥作用,进一步提高抑菌效率,其中:
二硫化钼(MoS2)纳米球作为光热剂,产生热量破坏细菌细胞,抑制细菌;
吸附在MoS2纳米球外层的MnO2可以与生物膜中过量的GSH反应,消耗GSH,同时生成Mn2+;Mn2+参与类Fenton反应,消耗生物膜中过表达的H2O2,产生有毒的·OH自由基;局部温度升高能促进·OH自由基的产生;·OH能增加细菌细胞膜的通透性和热敏性;从而更有效地杀灭细菌;
光热处理产生热量,提高局部温度,促进AIPH的热分解生成有毒的·R自由基,从而有效地杀灭细菌。
进一步地,上述一种多重疗法的抑菌复合材料中,MoS2纳米球尺寸在150~180nm,Mo S2/MnO2-AIPH纳米复合材料(MMA)的尺寸在190~210nm。
进一步地,上述一种多重疗法的抑菌复合材料中,各成分的质量百分比如下:MoS270%~75%、MnO2 15%~25%、AIPH 5%~10%,PEGDA 5%~10%。
进一步地,上述一种多重疗法的抑菌复合材料还包括聚乙二醇二丙烯酸酯(PEGDA),聚乙二醇二丙烯酸酯与MoS2/MnO2-AIPH纳米复合材料(MMA)混合后通过近红外光辅助光热聚合(NAPP)形成MoS2/MnO2-AIPH水凝胶(Gel(MoS2/MnO2-AIPH),Gel(MMA)),聚乙二醇二丙烯酸酯(PEGDA)可通过近红外光辅助光热聚合(NAPP)形成水凝胶,从而提高药物的生物利用度;水凝胶能够保持伤口周围湿润的环境,促进伤口愈合;当将AIPH应用于促进伤口愈合时,AIPH很难精确释放,因为它不能聚集在伤口周围,水凝胶用于负载AIPH并使其能够持续释放,因为其出色的生物安全性和生物相容性,能够在伤口部位原位生长,在保持伤口周围湿润环境的同时防止药物因流动而引起的损失。
本申请还提供了上述一种多重疗法的抑菌复合材料的制备方法,具体包括如下步骤:
S1:MoS2纳米球的制备:将0.5~0.75g钼酸钠·二水合物(Na2MoO4·2H2O)溶于25mL去离子水;超声5min后,用稀HCl(0.1M)调节pH至6.5±0.5;将1~1.5g L-半胱氨酸和50mL去离子水添加至该溶液;超声5min后加入0.025~0.05g聚乙烯吡咯烷酮(PVP);超声5min后移至不锈钢高压釜中,在200±20℃下反应24±2h;待溶液冷却后,离心(12000±2000rpm,10±1min);将沉淀洗涤多次得到MoS2纳米球;
S2:MoS2/MnO2的制备:称取50~75mg MoS2溶于25mL去离子水中,超声辅助均匀分散;向溶液中加入12.5~18.75mg KMnO4;搅拌一段时间后,逐滴滴加聚烯丙基胺盐酸盐(PAH)溶液(1~1.5mL,16mg/mL),继续以400~500rpm搅拌,离心后反复洗涤后即得到MoS2/MnO2纳米复合材料;
S3:MoS2/MnO2-AIPH的制备:将S2中制备的MoS2/MnO2纳米复合材料均匀分散于去离子水中,逐滴滴加AIPH水溶液,以400~500rpm搅拌混合反应形成MoS2/MnO2-AIPH(MMA);离心(12000±2000rpm,10±1min);将沉淀洗涤多次得到MoS2/MnO2-AIPH纳米复合材料(MMA)。
进一步地,上述一种多重疗法的抑菌复合材料的制备方法,还包括:
S4:MoS2/MnO2-AIPH水凝胶的制备:将S3中制备的MoS2/MnO2-AIPH纳米复合材料(MMA)溶液和聚乙二醇二丙烯酸酯(PEGDA)混合均匀,用808nm激光(1.0W/cm2)照射,利用激光辅助引发形成MoS2/MnO2-AIPH水凝胶(Gel(MoS2/MnO2-AIPH),Gel(MMA))。
进一步地,上述S1的MoS2纳米球的制备中,钼酸钠·二水合物与L-半胱氨酸的质量比为1:(1.5~2.5)。
进一步地,上述S1的MoS2纳米球的制备中,分散体系中Na2MoO4·2H2O的浓度为6~10mg/mL,L-半胱氨酸的浓度为13~20mg/mL。
进一步地,上述S2的MoS2/MnO2的制备中,MoS2纳米球与KMnO4的质量比例为(4~3.5):1,KMnO4与还原剂PAH的质量比例为1:(1.28~1.5)。
进一步地,上述S3的MoS2/MnO2-AIPH的制备中,MoS2/MnO2与AIPH的水溶液均匀分散于去离子水中,在磁力搅拌器上400~500rpm下搅拌反应10~12h。
进一步地,上述S3的MoS2/MnO2-AIPH的制备中,MoS2/MnO2与AIPH的质量比例为(0.25~1):1。
进一步地,上述S4的MoS2/MnO2-AIPH水凝胶的制备中,MoS2/MnO2-AIPH和PEGDA的浓度比为1:(9~14)。
进一步地,上述S4的MoS2/MnO2-AIPH水凝胶的制备中,MoS2/MnO2-AIPH和PEGDA的浓度分别固定为1mg/mL和9mg/mL,基于NAPP原理激光辅助引发形成MoS2/MnO2-AIPH水凝胶(Gel(MoS2/MnO2-AIPH,Gel(MMA))。
本申请还提供了上述一种多重疗法的抑菌复合材料在抑菌中的应用。
本申请还提供了上述一种多重疗法的抑菌复合材料在促进伤口愈合中的应用。
本申请还提供了上述一种多重疗法的抑菌复合材料在制备细菌感染治疗药物中的应用。
本申请还提供了上述一种多重疗法的抑菌复合材料在制备促进伤口愈合药物中的应用。
本申请还提供了上述一种多重疗法的抑菌复合材料的制备方法在制备抑菌和/或促进伤口愈合药物中的应用。
3.有益效果
本申请与现有技术相比,其有益效果在于:
(1)本申请提供的一种多重疗法的抑菌复合材料及其制备方法与应用,可以联合光热和化动力两种疗法进行协同抗菌,光热疗法(PTT)带来的热量不仅仅用来杀灭细菌,PTT引起的局部温度升高能促进化动力疗法(CDT)中·OH自由基的产生,从而更有效地杀灭细菌。而CDT产生的·OH能增加细菌细胞膜的通透性和热敏性。因此,PTT和CDT联合使用比两种单独的疗法具有更大的杀菌效果。
(2)本申请提供的一种多重疗法的抑菌复合材料及其制备方法与应用,具有良好的光热稳定性、优异的生物安全性和生物相容性。对正常细胞低毒,安全性高,可以应用于临床研究。
(3)本申请提供的一种多重疗法的抑菌复合材料及其制备方法与应用,药物原材料经济易得,水热法制备MoS2方便简单,产量大,且稳定性高,在连续4周时间内粒径均没有明显变化。
(4)本申请提供的一种多重疗法的抑菌复合材料及其制备方法与应用,在扫描电镜和粒径观察下,表现出良好的尺寸分布,MoS2纳米球尺寸在150~180nm,而终产物MMA的尺寸在190~210nm。
附图说明
图1是纳米材料的扫描电镜图和粒径图,其中I为MoS2纳米球、MoS2/MnO2及MMA的扫描电镜图片,II为相对应的MoS2纳米球和MMA的粒径图谱,III为MMA在4个星期内的粒径变化。
图2是紫外谱图和傅里叶变换红外谱图。
图3是光热效应图。其中I为辐照条件为2.0W/cm2,808nm时不同浓度(25、50、100μg/mL)下MMA的光热升温曲线,II为不同功率(0.5、1.0、2.0W/cm2)下MMA(100μg/mL)的光热升温曲线,III为MMA水溶液(100μg/mL)连续四个开/关循环的光热反应,IV不同浓度的MMA(25、50、100μg/mL)在2.0W/cm2下照射0、1、2、3、4和5min的光热图像,以PBS作为对照。
图4是MMA的化学动力性能评估。在有无NIR情况下,用MMA(100g/mL)处理的细胞内ROS的荧光图像,以等浓度的PBS和AIPH作为对照,NIR处理条件为2.0W/cm2,5min。
图5是MMA抗菌材料的体外抑菌试验效果图。其中I为不同对照组的试验效果图,II为不同浓度(25、50、75、100μg/mL)MMA的抑菌效果图。
图6是MMA处理下的流式细胞仪观察结果。
图7是MMA促伤口愈合效果图。
图8是MMA的生物安全评估。
图9是MMA的溶血实验。
具体实施方式
下面结合具体实施例对本申请进一步进行描述。
需要说明的是,本说明书中所引用的如“上”、“下”、“左”、“右”、“中间”等用语,亦仅为便于叙述的明了,而非用以限定可实施的范围,其相对关系的改变或调整,在无实质变更技术内容下,当亦视为本申请可实施的范畴。
除非另有定义,本文所使用的所有的技术和科学术语与属于本申请的技术领域的技术人员通常理解的含义相同;本文所使用的术语“和/或”包括一个或多个相关的所列项目的任意的和所有的组合。
实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
如本文所使用,术语“约”用于提供与给定术语、度量或值相关联的灵活性和不精确性。本领域技术人员可以容易地确定具体变量的灵活性程度。
如本文所使用,术语“......中的至少一个”旨在与“......中的一个或多个”同义。例如,“A、B和C中的至少一个”明确包括仅A、仅B、仅C以及它们各自的组合。
浓度、量和其他数值数据可以在本文中以范围格式呈现。应当理解,这样的范围格式仅是为了方便和简洁而使用,并且应当灵活地解释为不仅包括明确叙述为范围极限的数值,而且还包括涵盖在所述范围内的所有单独的数值或子范围,就如同每个数值和子范围都被明确叙述一样。例如,约1至约4.5的数值范围应当被解释为不仅包括明确叙述的1至约4.5的极限值,而且还包括单独的数字(诸如2、3、4)和子范围(诸如1至3、2至4等)。相同的原理适用于仅叙述一个数值的范围,诸如“小于约4.5,”应当将其解释为包括所有上述的值和范围。此外,无论所描述的范围或特征的广度如何,都应当适用这种解释。
实施例1
本实施例提供一种多重疗法的抑菌复合材料及其制备方法。
该复合材料为水凝胶包裹的以MoS2为载体且外层吸附MnO2和AIPH的协同光热和化动力疗法的抑菌和促伤口愈合材料。具体的,该复合材料核壳结构,其内核为具有较高光热转换效率的二硫化钼(MoS2)纳米球,中间层为通过静电吸附作用吸附在二硫化钼纳米球表面的二氧化锰(MnO2),外层为吸附在二氧化锰表面的2,2’-偶氮双[2-(2-咪唑啉-2-基)丙烷]二盐酸盐(AIPH),然后与聚乙二醇二丙烯酸酯(PEGDA)混合后通过近红外光辅助光热聚合(NAPP)形成的MoS2/MnO2-AIPH水凝胶(Gel(MoS2/MnO2-AIPH),Gel(MMA))。
本实施例还提供了上述一种多重疗法的抑菌复合材料的制备方法,具体包括如下步骤:
S1,MoS2纳米球的制备:
将0.5g钼酸钠·二水合物(Na2MoO4·2H2O)溶于25mL水中;超声5min后,用0.1MHCl调节pH至6.5;将1g L-半胱氨酸和50mL的水溶液添加至该溶液;超声5min后加入0.025g聚乙烯吡咯烷酮(PVP);再超声5min,移至200mL的不锈钢高压釜中,并在200℃下反应24h;待溶液冷却后,离心(12000rpm,10min);倒掉上清液,用乙醇、水、乙醇、水交替洗涤,后将沉淀滴少量去离子水溶解,放在烘箱中烘干,即得到MoS2纳米球颗粒。
S2,MoS2/MnO2的制备:
准确称取MoS2(50mg)溶于25mL去离子水中,超声辅助均匀分散;向上述溶液中加入KMnO4(12.5mg);搅拌一段时间后,逐滴滴加1mL PAH(16.0mg/mL),继续搅拌一段时间后,离心后反复洗涤后即得到MoS2/MnO2。
S3,MMA的制备:
将MoS2/MnO2(25mg)均匀分散于去离子水中,随后逐滴滴加AIPH水溶液(5mg/mL,20mL),继续搅拌10h,所得产物MoS2/MnO2-AIPH(MMA)于12000r/min离心,用去离子水清洗3遍。
S4,Gel(MMA)的制备:
将1mg MMA溶于1mL去离子水,将其置于磁力搅拌器上以400~500rpm条件下搅拌使其分散均匀;向上述溶液中加入9mL PEGDA继续搅拌5min,用808nm激光(1.0W/cm2)照射,利用激光辅助引发形成水凝胶(Gel(MMA))。
结果分析:
(1)扫描电镜观察和粒径观察
本申请使用扫描电镜和粒径表征制备的纳米抗菌材料,结果见图1。图1中I扫描电镜图显示,MoS2纳米球呈规则的球形,且分布均匀,大小在180nm左右,MoS2/MnO2和MoS2/MnO2-AIPH则呈现有明显的褶皱,说明表面成功负载有MnO2和AIPH,且尺寸增加到207nm左右。图1中II的粒径测试结果与扫描电镜相吻合。另外,根据图1中III粒径测量结果可知,MMA在水、PBS和10%胎牛血清(FBS)中的流体直径在4周内没有显著变化,表明MMA水溶液具有优异的稳定性。
(2)紫外和红外谱图
本申请中以MoS2为载体,同时包载MnO2和AIPH,紫外和红外表征结果见图2中I和II。由图2中的出峰位可以判断纳米复合抗菌材料成功合成。
(3)光热分析
测试所合成的复合纳米抗菌材料在不同浓度、不同功率下的光热效果。如图3中I和II,随着MMA的浓度从25μg/mL增加到100μg/mL,温度从40.4℃显著上升到75.5℃。同样,当MMA的浓度保持不变(100μg/mL)时,升温速率与辐射功率呈正相关证明了MMA优异的光热性能光热具有优异的光热效果。另外图3中III和IV显示出MMA具有良好的光热稳定性和优异的光热效果。
(4)化动力评估
本发明中MMA外层负载的MnO2可以利用生物膜高GSH的环境特点,参与类芬顿反应,产生有毒的活性氧。结果见图4,可以看出MMA可以产生活性氧,具有杀菌作用。
实施例3
本实施例提供MMA体外抑菌试验。
利用耐药性(MDR)金黄色葡萄球菌作为试验菌种,采用CFU法评价抑菌效果。结果见图5中I,设置不同组作为对照。图5中II为终产物MMA在不同浓度下的抑菌效果。结果表明,本发明的药物材料抗菌效果显著。
流式细胞仪分析结果:
荧光成像结合选择性染色活细胞和死细胞的染料可用于观察细胞损伤。在NIR处理条件下(2W/cm2,5min),MMA的荧光图像以大量红色染色的细胞(死亡)为特征,而MoS2组的图像仅以少量红色染色的细胞为特征,空白组包括所有绿色染色的细胞(活的)。这些差异表明MMA能够比MoS2纳米球更有效地杀死MDR大肠杆菌(图6)。
实施例4
本实施例提供Gel(MMA)促伤口愈合试验。
将100μL活化的多药耐药金黄色葡萄球菌(1×106CFU/mL)注射到每只小鼠的伤口中。根据小鼠的体重将小鼠分成六组(每组3-5只小鼠)以确保在实验前小鼠没有显著差异:空白组、MoS2/MnO2组、Gel(MMA)组、NIR照射+MoS2/MnO2组和NIR照射+Gel(MMA)组。对于暴露于NIR光的小鼠组,伤口用NIR光(2W/cm2)照射5min,治疗持续10天。期间拍照记录小鼠伤口变化。根据图7结果可知,本发明的纳米材料可以有效杀灭细菌并促进伤口愈合。
实施例5
本实施例提供MMA的生物安全性评估。
在小鼠胚胎成纤维细胞(MEF)和NCTC克隆929(L929)细胞中评价了MMA及其组分的细胞毒性。
首先,将细胞悬浮液转移到96孔板中,并将细胞在37℃下在板中培养24小时。向每个孔中加入100μL不同浓度(12.5、25、50、100、150和200μg/mL)的MMA水溶液,并将溶液进行NIR照射(2W/cm2)5分钟。在与MMA相同的条件下,使用MoS2和MoS2/MnO2作为对照。孵育24小时后,用PBS洗涤两次。细胞用CCK-8试剂染色30分钟,并测量每个孔的吸光度。
为了探索NIR照射和Gel(MMA)是否对小鼠的各种器官造成损伤,在空白组、NIR照射组、Gel(MMA)和Gel(MMA)+NIR四组中的每一组处理后,从小鼠身上切取心脏、肝脏、脾脏、肺和肾脏的切片,进行苏木精-伊红(H&E)染色。
根据图8结果可知,纳米复合材料MMA并不会引起正常细胞损伤。基于H&E染色结果,我们观察到与正常组相比,单独的NIR照射没有对实验组的小鼠造成器官损伤。此外,在用Gel(MMA)覆盖伤口后,在有或没有NIR照射的情况下,小鼠具有正常的心脏、肝脏、脾脏、肺和肾脏,并且没有观察到明显的炎症(图8)。这些结果表明本申请提供的多重疗法抑菌复合材料是无毒的,可以用于医学应用。
实施例6
本实施例提供MMA的生物相容性评估。
在本实施例中,进行了溶血试验。根据图9结果可知,MMA对血细胞没有明显的损害,具有良好的血液相容性。
Claims (10)
1.一种多重疗法的抑菌复合材料,其特征在于,所述多重疗法的抑菌复合材料为核壳结构,其内核为具有光热转换效率的二硫化钼纳米球,中间层为通过静电吸附作用吸附在二硫化钼纳米球表面的二氧化锰,外层为吸附在二氧化锰表面的2,2’-偶氮双[2-(2-咪唑啉-2-基)丙烷]二盐酸盐,最终形成为MoS2/MnO2-AIPH纳米复合材料。
2.根据权利要求1所述的一种多重疗法的抑菌复合材料,其特征在于,所述多重疗法的抑菌复合材料中,各成分的质量百分比如下:MoS2 70%~75%、MnO2 15%~25%、AIPH 5%~10%,PEGDA 5%~10%。
3.根据权利要求1或2所述的一种多重疗法的抑菌复合材料,其特征在于,所述二硫化钼纳米球尺寸为150~180nm,MoS2/MnO2-AIPH纳米复合材料的尺寸为190~210nm。
4.根据权利要求3所述的一种多重疗法的抑菌复合材料,其特征在于,所述多重疗法的抑菌复合材料还包括聚乙二醇二丙烯酸酯,聚乙二醇二丙烯酸酯与MoS2/MnO2-AIPH纳米复合材料混合后通过近红外光辅助光热聚合形成MoS2/MnO2-AIPH水凝胶。
5.权利要求1-4任一所述的一种多重疗法的抑菌复合材料的制备方法,其特征在于,具体包括如下步骤:
S1,MoS2纳米球的制备:将钼酸钠·二水合物溶于水中;超声后用稀HCl调节pH至6.5±0.5;将L-半胱氨酸和去离子水添加至该溶液;超声后加入聚乙烯吡咯烷酮;超声后移至不锈钢高压釜中,在200±20℃下反应24±2h;待溶液冷却后,离心,将沉淀洗涤多次得到MoS2纳米球;
S2,MoS2/MnO2的制备:将MoS2纳米球溶于去离子水中,超声辅助均匀分散;向溶液中加入KMnO4;搅拌一段时间后,逐滴滴加聚烯丙基胺盐酸盐溶液,继续搅拌后离心,反复洗涤即得到MoS2/MnO2纳米复合材料;
S3,MoS2/MnO2-AIPH的制备:将S2中制备的MoS2/MnO2纳米复合材料均匀分散于去离子水中,逐滴滴加AIPH水溶液,搅拌混合反应形成MoS2/MnO2-AIPH;离心;将沉淀洗涤多次得到MoS2/MnO2-AIPH纳米复合材料。
6.根据权利要求5所述的一种多重疗法的抑菌复合材料的制备方法,其特征在于,还包括步骤:
S4,MoS2/MnO2-AIPH水凝胶的制备:将S3中制备的MoS2/MnO2-AIPH纳米复合材料溶液和聚乙二醇二丙烯酸酯混合均匀,用激光照射,利用激光辅助引发形成MoS2/MnO2-AIPH水凝胶。
7.根据权利要求6所述的一种多重疗法的抑菌复合材料的制备方法,其特征在于,所述S1的MoS2纳米球的制备中,钼酸钠·二水合物与L-半胱氨酸的质量比为1:(1.5~2.5);
所述S2的MoS2/MnO2的制备中,MoS2纳米球与KMnO4的质量比例为(4~3.5):1,KMnO4与还原剂PAH的比例为1:(1.28~1.5);
所述S3的MoS2/MnO2-AIPH的制备中,MoS2/MnO2与AIPH的水溶液均匀分散于去离子水中,在磁力搅拌器上400~500rpm下搅拌反应10~12h;
所述S3的MoS2/MnO2-AIPH的制备中,MoS2/MnO2与AIPH的质量比例为(0.25~1):1。
8.根据权利要求7所述的一种多重疗法的抑菌复合材料的制备方法,其特征在于,所述S4的MoS2/MnO2-AIPH水凝胶的制备中,MoS2/MnO2-AIPH和PEGDA的浓度比为1:(9~14)。
9.权利要求1-4任一所述的多重疗法的抑菌复合材料在抑菌和/或促进伤口愈合中的应用。
10.权利要求1-4任一所述的多重疗法的抑菌复合材料和/或权利要求5-8任一所述的一种多重疗法的抑菌复合材料的制备方法,在制备抑菌和/或促进伤口愈合药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310385310.9A CN116421725A (zh) | 2023-04-07 | 2023-04-07 | 一种多重疗法的抑菌复合材料及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310385310.9A CN116421725A (zh) | 2023-04-07 | 2023-04-07 | 一种多重疗法的抑菌复合材料及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116421725A true CN116421725A (zh) | 2023-07-14 |
Family
ID=87086848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310385310.9A Pending CN116421725A (zh) | 2023-04-07 | 2023-04-07 | 一种多重疗法的抑菌复合材料及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116421725A (zh) |
-
2023
- 2023-04-07 CN CN202310385310.9A patent/CN116421725A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xiao et al. | Dual stimuli-responsive metal-organic framework-based nanosystem for synergistic photothermal/pharmacological antibacterial therapy | |
Wang et al. | Rapid and highly effective noninvasive disinfection by hybrid Ag/CS@ MnO2 nanosheets using near-infrared light | |
Zhang et al. | Near-infrared-triggered antibacterial and antifungal photodynamic therapy based on lanthanide-doped upconversion nanoparticles | |
Chen et al. | Recent advances in Ti-based MOFs in biomedical applications | |
Liu et al. | Manganese dioxide nanozyme for reactive oxygen therapy of bacterial infection and wound healing | |
Qi et al. | Infection microenvironment-activated core-shell nanoassemblies for photothermal/chemodynamic synergistic wound therapy and multimodal imaging | |
Chen et al. | Synergistic antibacterial mechanism and coating application of copper/titanium dioxide nanoparticles | |
Yang et al. | Growth Factor‐Decorated Ti3C2 MXene/MoS2 2D Bio‐Heterojunctions with Quad‐Channel Photonic Disinfection for Effective Regeneration of Bacteria‐Invaded Cutaneous Tissue | |
Wang et al. | Pd-Cu nanoalloy for dual stimuli-responsive chemo-photothermal therapy against pathogenic biofilm bacteria | |
Maurya et al. | Surface functionalization of TiO2 with plant extracts and their combined antimicrobial activities against E. faecalis and E. coli | |
Zhong et al. | Silver nanoparticles coated by green graphene quantum dots for accelerating the healing of MRSA-infected wounds | |
Tian et al. | Cu-GA-coordination polymer nanozymes with triple enzymatic activity for wound disinfection and accelerated wound healing | |
Wang et al. | Neighboring Carboxylic Acid Boosts Peroxidase‐Like Property of Metal‐Phenolic Nano‐Networks in Eradicating Streptococcus mutans Biofilms | |
Liu et al. | Near-infrared light-triggered nitric oxide release combined with low-temperature photothermal therapy for synergetic antibacterial and antifungal | |
Ye et al. | The CuO and AgO co-modified ZnO nanocomposites for promoting wound healing in Staphylococcus aureus infection | |
Guo et al. | A bifunctional nanoplatform based on copper manganate nanoflakes for bacterial elimination via a catalytic and photothermal synergistic effect | |
Zhang et al. | A nanoplatform with oxygen self-supplying and heat-sensitizing capabilities enhances the efficacy of photodynamic therapy in eradicating multidrug-resistant biofilms | |
Liu et al. | Facile synthesis of tannic acid modified NbTe2 nanosheets for effective photothermal ablation of bacterial pathogens | |
Li et al. | Cytocompatible amphipathic carbon quantum dots as potent membrane-active antibacterial agents with low drug resistance and effective inhibition of biofilm formation | |
Jia et al. | Silver nanoparticles anchored magnetic self-assembled carboxymethyl cellulose-ε-polylysine hybrids with synergetic antibacterial activity for wound infection therapy | |
Zhang et al. | Hydrogen plasma treated-Ce-BTC nanorods enable enhanced antibacterial activity and soft tissue sealing ability | |
Qi et al. | Facile synthesis of ε-poly-L-lysine-conjugated ZnO@ PDA as photothermal antibacterial agents for synergistic bacteria killing and biofilm eradication | |
Zhang et al. | Electrospun nanofibrous membranes loaded with IR780 conjugated MoS2-nanosheet for dual-mode photodynamic/photothermal inactivation of drug-resistant bacteria | |
Chai et al. | Enhanced antibacterial activity of silica nanorattles with ZnO combination nanoparticles against methicillin-resistant Staphylococcus aureus | |
Wang et al. | NIR-II photo-amplified peroxidase-like activity using biocatalytic copper-based nanoplatform against subcutaneous methicillin-resistant Staphylococcus aureus infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |